Vilastobart clinical trials
Also written XTX-101.
How each study uses vilastobart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the vilastobart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
Xilio Development, Inc. (1) · Medical College of Wisconsin (1) · Massachusetts General Hospital (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses vilastobart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Triplet Immunotherapy For Exhausted Cell Targets in Advanced Squamous Cell CarcinomaNot yet recruitingPhase 2Medical College of WisconsinNCT07896811Written as Vilastobart
- Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PCNot yet recruitingPhase 2Massachusetts General HospitalNCT07765836Written as vilastobart (XTX101)
- Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid TumorsCompletedPhase 1/2Xilio Development, Inc.NCT04896697Written as vilastobart (XTX101)
Codes
What other systems call vilastobart · ClinicalTrials.gg INT015658
- UNII (FDA) 8FUE2D4G82VILASTOBARTOne source FDA
- NCI Thesaurus C203034VilastobartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8FUE2D4G82 | VILASTOBART | One source FDA |
| NCI Thesaurus | C203034 | Vilastobart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.